Vaxart shares are trading higher after the company reported topline results from its Phase 1 trial evaluating second-generation oral norovirus vaccine constructs.

0.00%

Vaxart, Inc

VXRT

0.00

Vaxart shares are trading higher after the company reported topline results from its Phase 1 trial evaluating second-generation oral norovirus vaccine constructs.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Breakthrough And Pullback | 6 Stocks Deserve Close Attention: DDOG, MDU And More

Tenaya Therapeutics Says Expects No Impact On TN-201 Timelines From Hold; Says Working To Resolve Clinical Hold And Resume Dosing

BRIEF-Metsera Says Pfizer to Buy Metsera For Up To $86.25 Per Share

Is BioCryst’s Surging ORLADEYO Sales and Astria Deal Reshaping the Investment Case for BCRX?

A Fresh Look at Madrigal Pharmaceuticals (MDGL) Valuation Following New Rezdiffra Data and Earnings Update

Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Third-Quarter Results

Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio?

A Look at MannKind (MNKD) Valuation Following Strong Revenue Beat and scPharmaceuticals Acquisition